Literature DB >> 1809584

Vitiligo and cutaneous melanoma. A case study.

K U Schallreuter1, C Levenig, J Berger.   

Abstract

The examination of 623 melanoma patients in North Germany yielded the depigmentation disorder vitiligo in 23 cases (i.e. 3.7%). In 11 patients, the disease preceded their tumor, whereas in 11 patients, vitiligo developed after diagnosis of primary and/or metastatic melanoma into the regional lymph nodes. In 1 case, the onset of melanoma in relation to the tumor remained undefined. The prevalence of vitiligo increased with tumor risk factors based on tumor thickness and anatomical site of tumor location (i.e. for low risk 1.75%, intermediate risk 5.2% and high risk 5.8%). A comparison of the prevalence of vitiligo to the normal population of Northwestern Europe (i.e. 0.38-0.57%) showed a 7- to 10-fold increase for the patients with melanoma. A reverse analysis of the data yielded a 180-fold higher prevalence of melanoma in the group of patients with vitiligo. These results strongly support a more thorough examination of patients with vitiligo for primary melanoma.

Entities:  

Mesh:

Year:  1991        PMID: 1809584     DOI: 10.1159/000247693

Source DB:  PubMed          Journal:  Dermatologica        ISSN: 0011-9075


  16 in total

Review 1.  Prognostic significance of autoimmunity during treatment of melanoma with interferon.

Authors:  Michal T Krauze; Ahmad Tarhini; Helen Gogas; John M Kirkwood
Journal:  Semin Immunopathol       Date:  2011-01-31       Impact factor: 9.623

Review 2.  Melanoma-associated leukoderma - immunology in black and white?

Authors:  Hadas Prag Naveh; Uma N M Rao; Lisa H Butterfield
Journal:  Pigment Cell Melanoma Res       Date:  2013-10-09       Impact factor: 4.693

3.  Vitiligo-like Depigmentation Associated with Metastatic Melanoma of an Unknown Origin.

Authors:  Eun Ah Cho; Myung Ah Lee; Hoon Kang; Seung Dong Lee; Hyung Ok Kim; Young Min Park
Journal:  Ann Dermatol       Date:  2009-05-31       Impact factor: 1.444

Review 4.  Management of the cutaneous adverse effects of antimelanoma therapy.

Authors:  Rose Congwei Liu; Germana Consuegra; Pablo Fernández-Peñas
Journal:  Melanoma Manag       Date:  2017-11-22

5.  Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa.

Authors:  Ahmad A Tarhini; Donghoon Shin; Sandra J Lee; Joseph Stuckert; Cindy A Sander; John M Kirkwood
Journal:  Melanoma Res       Date:  2014-04       Impact factor: 3.599

6.  A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.

Authors:  Z J Wolner; A A Marghoob; M P Pulitzer; M A Postow; M A Marchetti
Journal:  Br J Dermatol       Date:  2017-09-21       Impact factor: 9.302

7.  [Vitiligo. What is new?].

Authors:  K U Schallreuter; M M A E L Salem
Journal:  Hautarzt       Date:  2010-07       Impact factor: 0.751

8.  [Vitiligo: Clinical presentation and pathogenesis].

Authors:  M Schild; M Meurer
Journal:  Hautarzt       Date:  2016-02       Impact factor: 0.751

9.  Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.

Authors:  Helen Gogas; Urania Dafni; Henry Koon; Maria Spyropoulou-Vlachou; Yannis Metaxas; Elizabeth Buchbinder; Eirini Pectasides; Dimosthenis Tsoutsos; Aristidis Polyzos; Alexandros Stratigos; Christos Markopoulos; Petros Panagiotou; George Fountzilas; Ourania Castana; Pantelis Skarlos; Michael B Atkins; John M Kirkwood
Journal:  J Transl Med       Date:  2010-11-03       Impact factor: 5.531

10.  Vitiligo: a review of some facts lesser known about depigmentation.

Authors:  James J Nordlund
Journal:  Indian J Dermatol       Date:  2011-03       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.